Arindam Chakrabarti1, Allen Nguyen2, Margaret M Newhams3, Maikke B Ohlson1,4, Xiaoying Yang5, Sheila Ulufatu6, Shannon Liu6, Summer Park7, Min Xu7, Jenny Jiang2, Wendy G Halpern8, Veronica G Anania2, Jacqueline M McBride2, Carrie M Rosenberger1, Adrienne G Randolph3,9. 1. Biomarker Discovery, Genentech, Inc., South San Francisco, California, USA. 2. Biomarker Development, Genentech, Inc., South San Francisco, California, USA. 3. Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts, USA. 4. Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5. Biostatistics, Genentech, Inc., South San Francisco, California, USA. 6. Department of Safety Assessment, Genentech, Inc., South San Francisco, California, USA. 7. Translational Immunology, Genentech, Inc., South San Francisco, California, USA. 8. Department of Pathology, Genentech, Inc., South San Francisco, California, USA. 9. Departments of Anaesthesia and Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Biomarkers that can risk-stratify children with influenza virus lower respiratory infection may identify patients for targeted intervention. Early elevation of alveolar-related proteins in the bloodstream in these patients could indicate more severe lung damage portending worse outcomes. METHODS: We used a mouse model of human influenza infection and evaluated relationships between lung pathophysiology and surfactant protein D (SP-D), SP-A, and Club cell protein 16 (CC16). We then measured SP-A, SP-D, and CC16 levels in plasma samples from 94 children with influenza-associated acute respiratory failure (PICFLU cohort), excluding children with underlying conditions explaining disease severity. We tested for associations between levels of circulating proteins and disease severity including the diagnosis of acute respiratory distress syndrome (ARDS), mechanical ventilator, intensive care unit and hospital days, and hospital mortality. RESULTS: Circulating SP-D showed a greater increase than SP-A and CC16 in mice with increased alveolar-vascular permeability following influenza infection. In the PICFLU cohort, SP-D was associated with moderate-severe ARDS diagnosis (p = 0.01) and with mechanical ventilator (r = 0.45, p = 0.002), ICU (r = 0.44, p = 0.002), and hospital days (r = 0.37, p = 0.001) in influenza-infected children without bacterial coinfection. Levels of SP-D were lower in children with secondary bacterial pneumonia (p = 0.01) and not associated with outcomes. CC16 and SP-A levels did not differ with bacterial coinfection and were not consistently associated with severe outcomes. CONCLUSIONS: SP-D has potential as an early circulating biomarker reflecting a degree of lung damage caused directly by influenza virus infection in children. Secondary bacterial pneumonia alters SP-D biomarker performance.
BACKGROUND: Biomarkers that can risk-stratify children with influenza virus lower respiratory infection may identify patients for targeted intervention. Early elevation of alveolar-related proteins in the bloodstream in these patients could indicate more severe lung damage portending worse outcomes. METHODS: We used a mouse model of human influenza infection and evaluated relationships between lung pathophysiology and surfactant protein D (SP-D), SP-A, and Club cell protein 16 (CC16). We then measured SP-A, SP-D, and CC16 levels in plasma samples from 94 children with influenza-associated acute respiratory failure (PICFLU cohort), excluding children with underlying conditions explaining disease severity. We tested for associations between levels of circulating proteins and disease severity including the diagnosis of acute respiratory distress syndrome (ARDS), mechanical ventilator, intensive care unit and hospital days, and hospital mortality. RESULTS: Circulating SP-D showed a greater increase than SP-A and CC16 in mice with increased alveolar-vascular permeability following influenza infection. In the PICFLU cohort, SP-D was associated with moderate-severe ARDS diagnosis (p = 0.01) and with mechanical ventilator (r = 0.45, p = 0.002), ICU (r = 0.44, p = 0.002), and hospital days (r = 0.37, p = 0.001) in influenza-infected children without bacterial coinfection. Levels of SP-D were lower in children with secondary bacterial pneumonia (p = 0.01) and not associated with outcomes. CC16 and SP-A levels did not differ with bacterial coinfection and were not consistently associated with severe outcomes. CONCLUSIONS: SP-D has potential as an early circulating biomarker reflecting a degree of lung damage caused directly by influenza virus infection in children. Secondary bacterial pneumonia alters SP-D biomarker performance.
Authors: Shyra J Gardai; Yi-Qun Xiao; Matthew Dickinson; Jerry A Nick; Dennis R Voelker; Kelly E Greene; Peter M Henson Journal: Cell Date: 2003-10-03 Impact factor: 41.582
Authors: Adrienne G Randolph; Wai-Ki Yip; Emma Kaitlynn Allen; Carrie M Rosenberger; Anna A Agan; Stephanie A Ash; Yu Zhang; Tushar R Bhangale; David Finkelstein; Natalie Z Cvijanovich; Peter M Mourani; Mark W Hall; Helen C Su; Paul G Thomas Journal: J Infect Dis Date: 2017-07-01 Impact factor: 5.226
Authors: Gautham K Rao; Rodney A Prell; Steven T Laing; Stefanie C M Burleson; Allen Nguyen; Jacqueline M McBride; Crystal Zhang; Daniel Sheinson; Wendy G Halpern Journal: Toxicol Sci Date: 2019-06-01 Impact factor: 4.849
Authors: Rogier M Determann; Annick A N M Royakkers; Jack J Haitsma; Haibo Zhang; Arthur S Slutsky; V Marco Ranieri; Marcus J Schultz Journal: BMC Pulm Med Date: 2010-02-16 Impact factor: 3.317
Authors: Rogier M Determann; Julian L Millo; Sam Waddy; Rene Lutter; Chris S Garrard; Marcus J Schultz Journal: BMC Pulm Med Date: 2009-12-03 Impact factor: 3.317
Authors: Adrienne G Randolph; Ruifei Xu; Tanya Novak; Margaret M Newhams; Juliane Bubeck Wardenburg; Scott L Weiss; Ronald C Sanders; Neal J Thomas; Mark W Hall; Keiko M Tarquinio; Natalie Cvijanovich; Rainer G Gedeit; Edward J Truemper; Barry Markovitz; Mary E Hartman; Kate G Ackerman; John S Giuliano; Steven L Shein; Kristin L Moffitt Journal: Clin Infect Dis Date: 2019-01-18 Impact factor: 9.079